Aluminium Chloride Hexahydrate
Brand names: Driclor, Anhydrol Forte
Aluminium chloride hexahydrate is a topical antiperspirant used to treat hyperhidrosis (excessive sweating) of the axillae, palms and soles.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It forms an obstructive precipitate within the sweat duct that physically blocks eccrine sweat secretion, reducing localised sweating.
Prescribing in practice
- Skin irritation is common; it should be applied to dry, intact skin and not to broken, recently shaved or inflamed skin to reduce stinging and irritation.
- Apply at night to clean dry skin and wash off in the morning, reducing application frequency once sweating improves.
- Avoid contact with the eyes and mucous membranes.
Monitoring
Monitoring is clinical, reviewing the response and any local skin irritation.
Counselling the patient
- Apply at night to thoroughly dry skin and wash off the next morning.
- Do not shave the area immediately before applying to avoid stinging.
- Reduce how often you apply it once sweating is better controlled.
Evidence & guidelines
Topical aluminium salts are recommended as first-line treatment for primary focal hyperhidrosis in current prescribing references.
Reference: NICE CKS Hyperhidrosis (2023); International Hyperhidrosis Society guidelines; BAD patient information on hyperhidrosis; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD